PHARM Pharming Group N.V.
Price Chart
Executive Summary
Pharming Group reported strong full-year 2025 results with 27% revenue growth to $376.1 million, driven by RUCONEST® and Joenja®. The company achieved its first annual operating profit ($25.8 million) and positive operating cash flow ($54.7 million), while providing 2026 revenue guidance of $405–$425 million. However, a recent FDA Complete Response Letter for Joenja®'s pediatric label expansion introduces regulatory risk.
Key Financial Metrics
Actionable Insight
The stock may react positively to the strong financial turnaround and growth guidance, but traders should monitor the FDA dialogue on Joenja®'s pediatric expansion and upcoming Phase II readouts as key catalysts. The CRL introduces near-term regulatory risk that could limit upside despite strong commercial performance.
Key Facts
- Full-year 2025 revenue increased 27% YoY to $376.1 million
- Achieved $25.8 million operating profit in 2025 vs. $8.6 million loss in 2024
- Net cash flow from operations was $54.7 million in 2025 vs. negative in 2024
- 2026 revenue guidance of $405–$425 million (8%–13% growth)
- FDA issued Complete Response Letter for Joenja® pediatric sNDA, requesting additional PK data
- Phase II readouts for leniolisib in broader PIDs expected in second half of 2026
Financial Impact
Revenue up 27% to $376.1M, operating profit turned positive at $25.8M, cash flow from operations $54.7M
Risk Factors
- FDA Complete Response Letter delays pediatric approval of Joenja®
- Foreign exchange volatility impacting financial results
- Execution risk in advancing pipeline, particularly FALCON study completion and readout
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254281 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
17d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
May 7, 2026
5w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
May 7, 2026
5w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 23, 2026
7w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 7, 2026
9w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 2, 2026
10w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 27, 2026
11w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 24, 2026
11w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 12, 2026
13w ago
|
Press Release
| — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access